Lyra Therapeutics, Inc.
No enriched coverage for $LYRA in the last 7 days.
No SEC Form 4 filings for $LYRA in the last 30 days.
Lyra Therapeutics director W. Bradford Smith reported a disposition of 640 common shares back to the company, leaving him with no directly held shares. This transaction, coded as a disposition to the issuer at $0.00 per share, was detailed in a Form 4 filing. The disposition implies the shares were returned to the company rather than being sold on the open market.
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics ( NASDAQ:LYRA ) , a clinical-stage biotechnology company focused on chronic rhinosinusitis ( CRS ) treatments, reported its second quarter 2025 results on August 12, 2025. The most noteworthy item was the recent pivotal ENLIGHTEN 2 clinical trial win for its primary product ...
